SCHEMBL2278112

SCHEMBL2278112

CCCC(NC(CC(C)C)C1(c2ccc(Cl)cc2)CCC1)C(=O)OCC

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 17/20 0.73
SLC6A3 Q01959 17/20 0.73
SLC6A2 P23975 16/20 0.73
CYP3A4 P08684 2/20 0.46
ALOX15 P16050 2/20 0.46
TSHR P16473 2/20 0.46
TP53 P04637 1/20 0.46
CHRM2 P08172 1/20 0.45
ADRA2A P08913 1/20 0.45
ADRA2B P18089 1/20 0.45
ADRA2C P18825 1/20 0.45
HTR2A P28223 1/20 0.45
OPRK1 P41145 1/20 0.45
HTR2B P41595 1/20 0.45
KCNH2 Q12809 1/20 0.45
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.44
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2274659 0.92 SLC6A4 (0.86) SLC6A4SLC6A3SLC6A2CYP3A4ALOX15
SCHEMBL2273403 0.84 SLC6A4 (1.00) SLC6A4SLC6A3SLC6A2CYP3A4ALOX15
SCHEMBL2272723 0.82 SLC6A4 (0.81) SLC6A4SLC6A3SLC6A2CYP3A4ALOX15
SCHEMBL2279418 0.80 SLC6A4 (0.77) SLC6A4SLC6A3SLC6A2CYP3A4ALOX15
SCHEMBL2270926 0.80 SLC6A4 (0.61) SLC6A4SLC6A3SLC6A2CYP3A4ALOX15
SCHEMBL13010911 0.77 SLC6A4 (0.55) SLC6A4SLC6A3SLC6A2CYP3A4ALOX15
SCHEMBL12235313 0.76 SLC6A2 (0.64) SLC6A4SLC6A3SLC6A2CYP3A4ALOX15
SCHEMBL14089440 0.75 SLC6A4 (0.60) SLC6A4SLC6A3SLC6A2CYP3A4ALOX15
SCHEMBL14089422 0.75 SLC6A4 (0.60) SLC6A4SLC6A3SLC6A2CYP3A4ALOX15
SCHEMBL871438 0.74 SLC6A2 (0.68) SLC6A4SLC6A3SLC6A2CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2066329-B1 SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOBUTYLMETHYLAMINES REVIVA PHARMACEUTICALS INC (US) 2017-09-06 EP disclosed
US-9302981-B2 Synthesis, methods of using, and compositions of cycloalkylmethylamines REVIVA PHARMACEUTICALS, INC. (US) 2016-04-05 US disclosed
US-20140194508-A1 SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES REVIVA PHARMACEUTICALS, INC. (US) 2014-07-10 US disclosed
US-8669285-B2 Synthesis, methods of using, and compositions of cycloalkylmethylamines REVIVA PHARMACEUTICALS, INC. (US) 2014-03-11 US disclosed
US-20130231386-A1 SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES REVIVA PHARMACEUTICALS, INC. (US) 2013-09-05 US disclosed
US-8445714-B2 Cycloalkylmethylamines REVIVA PHARMACEUTICALS, INC. (US) 2013-05-21 US disclosed
US-8372883-B2 Methods of using cycloalkylmethylamines REVIVA PHARMACEUTICALS, INC. (US) 2013-02-12 US disclosed
US-8338632-B2 Cycloalkylmethylamines REVIVA PHARMACEUTICALS, INC. (US) 2012-12-25 US disclosed
US-20110263704-A1 Methods of Using Cycloalkylmethylamines REVIVA PHARMACEUTICALS, INC. (US) 2011-10-27 US disclosed
US-20110263877-A1 Cycloalkylmethylamines REVIVA PHARMACEUTICALS, INC. (US) 2011-10-27 US disclosed
US-20110263888-A1 Cycloalkylmethylamines REVIVA PHARMACEUTICALS, INC. (US) 2011-10-27 US disclosed
US-7989500-B2 Synthesis, methods of using, and compositions of cycloalkylmethylamines REVIVA PHARMACEUTICALS, INC. (US) 2011-08-02 US disclosed
US-20080139663-A1 Cycloalkylmethylamine analogs; use treating obesity or related co-morbid indications REVIVA PHARMACEUTICALS, INC. 2008-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263704-A1 Methods of Using Cycloalkylmethylamines AADAC, PNMT, INMT SLC6A4 111/4885SLC6A3 274/4885SLC6A2 465/4885
US-20110263888-A1 Cycloalkylmethylamines AADAC, GPR119, INMT SLC6A4 126/4885SLC6A3 275/4885SLC6A2 434/4885
US-20140194508-A1 SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES AADAC, INMT, AADAT SLC6A4 229/4885SLC6A3 541/4885SLC6A2 925/4885
US-20080139663-A1 Cycloalkylmethylamine analogs; use treating obesity or related co-morbid indications AADAC, GPR119, MC4R SLC6A4 108/4885SLC6A3 204/4885SLC6A2 317/4885
US-20110263877-A1 Cycloalkylmethylamines AADAC, GPR119, INMT SLC6A4 126/4885SLC6A3 275/4885SLC6A2 434/4885
US-20130231386-A1 SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES AADAC, INMT, AADAT SLC6A4 229/4885SLC6A3 541/4885SLC6A2 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.